Kornimate/medical-research-clean huggingface dataset:
normal saline nebulization on prevention of extubation failure in neonates

Conditions: Neonatal Respiratory Failure

Summary: this study is about evaluating the effect of using normal saline nebulization in preventing re-intubation in extubated neonates , provided that the cause of intubation is mainly due to respiratory cause

using nebulization is of great debate in neonates especially post extubation as neonates have physiological characteristics such as difficult airway maintenance and clearance, smaller airway caliber, compliant chest wall, poor airway stability, and lower functional residual capacity that account for the diminished delivery of inhaled aerosol. nebulized normal saline has historically been used as a placebo typically in studies examining bronchodilator medications and sputum expectorants or used as a carrier to medications. nowadays, normal saline is a method of enhancing mucociliary clearance has become a clinically accepted adjunct to physiotherapy in the treatment of many chronic lung conditions . the effect of whether or not nebulization really improves the lung condition is evaluated by lung ultrasound ,it is not only useful in predicting failure of non-invasive ventilation and the need for invasive ventilation, but also has a great value in anticipating extubation success in general, patients with lower lung ultrasound scores show a better chance of extubation success. each lung will be divided into 3 areas (upper anterior, lower anterior, and lateral) and will be examined using a linear microprobe through both transverse and longitudinal scans. for each lung area, a 0- to 3-point score was given (total score ranging from 0-18).

Eligibility criteria:
inclusion criteria: * ventilated babies with primary respiratory disease as the provisional and primary cause of intubation immediately post-extubation. exclusion criteria: * neurological, cardiac, surgical or metabolic problems affecting their respiration. upper obstructive air way disease that might affect the success of extubation.
non-interventional study of patients using norditropin® for growth hormone deficiency or turner syndrome

Conditions: Growth Hormone Disorder; Growth Hormone Deficiency in Children; Genetic Disorder; Turner Syndrome

Summary: this study is conducted in japan. the aim of this study is to collect information about the efficacy and safety of norditropin® (somatropin) in the long-term treatment of short stature with ghd (growth hormone deficiency) where epiphysial discs are not closed and short stature with turner syndrome where epiphysial discs are not closed.


Eligibility criteria:
inclusion criteria: * growth hormone deficiency or short stature due to turner syndrome where the epiphyseal discs are not closed exclusion criteria: * diabetic * patients with malignant tumors * women who are either pregnant or likely to be pregnant * known or suspected allergy to study product(s) or related products
effect of the scot-heart 2 trial on lifestyle.

Conditions: Coronary Artery Disease; Primary Prevention

Summary: this study will recruit 400 participants who are taking part in the computed tomography coronary angiography for the prevention of myocardial infarction (scot-heart 2) trial. the investigator will assess diet, activity and habits at the start of the study and 6 months later. this will help us understand the effects taking part in the study may have on lifestyle. in addition, for participants who have ct scans, the investigator will present the results of the heart from the ct scan. this will help us understand how best to explain the results of the ct scan to patients.

this is a sub-study of the scot-heart 2 trial (which aims to determine the best way to prevent heart attacks). the purpose of this sub-study is to determine the effect of getting information on heart disease risk on lifestyle. at present doctors usually use a "risk score" to identify people at risk of heart disease who may benefit from medical treatment. in the scot-heart 2 study the investigator will compare this "risk score" to a specialised heart scan (a computed tomography coronary angiogram or ctca scan). in this study the investigator would like to understand more about the effects of receiving this information about the heart on lifestyle, including effects on smoking, diet and activity. this study will recruit 400 participants who are taking part in the scot-heart 2 trial. the investigator will assess lifestyle by using a detailed questionnaire which will be done at the start of the study and 6 months later. the investigator will also perform some simple investigations including a carbon monoxide breath test, blood pressure tests and measurements of activity such as step counts. this will help us understand the effects on lifestyle of getting information about a "risk score" or having a ct scan. in addition, for people who have ct scans the investigator will either provide a verbal explanation of the results, as is usual, or show pictures of the heart from the ct scan. this will help us understand how best to explain the results of the ct scan to partipants.

Eligibility criteria:
inclusion criteria: * must be enrolled in scotheart 2 trial exclusion criteria: * must be enrolled in scotheart 2 trial
relieving vasomotor symptoms effectively with bioidentical hormone replacement therapy: the revert study

Conditions: Menopause

Summary: bioidentical hormone replacement therapy (bhrt) to assess a change in the number of various menopausal symptoms such as hot flashes and night sweats in surgically or naturally induced peri or post-menopausal women.

participants will be receiving a customized bioidentical hormone regimen which may include a combination of estrogens, progesterone, and testosterone.

Eligibility criteria:
inclusion criteria: * participants must be women who are in surgically or naturally induced menopause or perimenopause, as determined by their physician. * participants must be starting a new regimen of bioidentical hormone replacement therapy. * participants must be expected to receive therapy for at least 12 weeks. * participants must be between 30 and 65 years of age. * participants must be able to provide sound written informed consent or have an acceptable surrogate capable of giving consent on the subject's behalf. exclusion criteria: * participants must not have prior hypersensitivity or adverse events to any of the components in the customized prescription. * participants must not be pregnant or breastfeeding women. * participants must not be managed outside the medimix specialty pharmacy system with regard to their bioidentical hormone replacement therapy. * participants must not be using another bioidentical hormone at the time of enrollment.

Keywords: bioidentical hormone replacement therapy
orofacial pain in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: although the orofacial pain is not typical symptom of multiple sclerosis, more than 50% of the patients experience some kind of pain. acute pain usually in form of trigeminal neuralgia, that occurred in 2-3% of patients with multiple sclerosis. chronic pain occurred in 40-50% of patients and most common forms are headache. aim of this study is to investigate prevalence and evaluate the form of orofacial pain in patients with multiple sclerosis treated in general hospital varaždin in period from 01.01. 2017. to 31.12.2022. results of this investigation will determine better understanding orofacial pain , treatment and impact on everyday life.

multiple sclerosis is a chronic autoimmune disease with an unknown mechanism of origin. although pain is not a typical symptom of multiple sclerosis, it occurs in more than 50% of patients and has significant impact on the quality of life of patients. pain syndromes that patients with multiple sclerosis initially have characteristics of somatic and nociceptive pain, and later neuropathic, including trigeminal neuralgia, headaches, lhermitte's syndrome. pain is also often associated with anxiety and depression, which occurs in almost one third of patients. pain therapy in these patients is a challenge for many doctors involved in the treatment. many patients do not have adequate pain therapy due to the disproportion between the fear of interaction with other drugs and side effects, and on the other hand the treatment of basic diseases with the aim of controlling the immune response.

Eligibility criteria:
inclusion criteria: * multiple scerosis * age 18-85 years exclusion criteria: * records with missing data

Keywords: facial pain craniofacial pain multiple sclerosis
patient-centered weight loss program for knee replacement patients

Conditions: ARTHROPLASTY, REPLACEMENT

Summary: pace is a patient-centered weight loss program that was developed specifically for knee replacements based on input from stakeholders, including knee replacement patients, physical therapists, and orthopedic surgeons. in this pilot study, participants undergoing knee replacement will be randomized to either start a weight loss program before surgery (pace) or after surgery (delayed pace). both programs will receive a 14-week intervention and complete assessments at baseline (up to 6 weeks prior to surgery), 12 weeks after surgery, and 26 weeks after surgery.

it is estimated that half of patients diagnosed with knee osteoarthritis (oa) will need a total knee replacement (tkr) during their lifetime. of patients who need a tkr, 80-95% are overweight or obese. while patients are encouraged to lose weight, limited, if any, guidance is provided to achieve recommended weight loss. many patients perceive that tkr is a necessary precursor for the initiation of weight loss. yet, 66% of patients actually gain weight by 2 years after surgery. patients undergoing tkr not only face unique barriers (i.e., pain, mobility limitations, motivation) to weight loss, but also have to balance pre- and post-operative concerns from physicians, surgeons, and rehabilitation specialists. to best accommodate the needs of both patients (pre- and post-tkr) and healthcare professionals (i.e., surgeon, physical therapist), patient and stakeholder engagement and activation is imperative in the development of a patient-centered weight loss intervention. investigators completed 20 interviews with patients pre- and post-tkr and identified weight loss barriers, preferred intervention components (e.g., delivery method, contact frequency, self-monitoring modality) and patient-reported outcomes (e.g., physical function, pain) viewed as critical by patients. investigators developed a patient-centered weight loss program (pace) guided by these results and additional input from stakeholders to meet the needs of patients and healthcare professionals. pace is a randomized pilot study comparing weight loss and patient-reported outcomes between pace (program starting up to 6 weeks pre-tkr to 12 weeks post-tkr) and delayed pace (program starting 12 weeks post-tkr to 26 weeks post-tkr).

Eligibility criteria:
inclusion criteria: * bmi between 25-45 kg/m2 * have a scheduled knee replacement at least 1 week away from baseline assessment * obtain physician approval to participate * english speaking * willing to attend 3 in-person assessments. exclusion criteria: * have any contraindications to diet or weight loss * undergoing simultaneous bilateral knee replacement or have a scheduled or anticipated knee replacement for the contralateral knee in the next 26 weeks * have a mobility limiting comorbidity besides relating to tkr * taking anti-obesity medications * enrolled in a formal weight loss program * have had or is planning to have bariatric/gastric/lapband surgery * is planning to relocate out of the chicago land area in the next 12 months.
the study of an investigational drug, patisiran (aln-ttr02), for the treatment of transthyretin (ttr)-mediated amyloidosis in participants who have already been treated with aln-ttr02 (patisiran)

Conditions: Amyloidosis

Summary: the purpose of this study is to evaluate the safety and efficacy of long-term dosing with aln-ttr02 (patisiran) in participants with transthyretin (ttr) mediated amyloidosis (attr).


Eligibility criteria:
inclusion criteria: * have completed a patisiran study (i.e., completed the last efficacy visit in the parent study) and, in the opinion of the investigator, tolerated study drug * be willing and able to comply with the protocol-required visit schedule and visit requirements and provide written informed consent exclusion criteria: * any new or uncontrolled condition that could make the participant unsuitable for participation

Keywords: rnai therapeutic fap familial amyloid polyneuropathy ttr transthyretin amyloidosis
a dose escalation study of proton and carbon ion irradiation for her2 positive and triple negative breast cancer

Conditions: Triple Negative Breast Cancer; HER2-positive Breast Cancer

Summary: adjuvant radiotherapy is the standard treatment for early breast cancer after breast conserving surgery. molecular subtypes was significantly associated with the risk of local recurrence of breast cancer. nguyen et al found that the overall 5-year cumulative incidence of local recurrence was 0.8% for luminal a, 1.5% for luminal b, 8.4% for her2 positive, and 7.1% for triple negative breast cancer after lumpectomy and radiotherapy. her2 positive and triple negative breast cancers may be inherently radioresistant. therefore, for her2 positive and triple negative breast cancer with high local recurrence and radiation resistance, proton combined with carbon ion is proposed after breast conserving surgery.


Eligibility criteria:
inclusion criteria: * histologically confirmed her2 positive or triple negative invasive breast carcinoma.(her2 positive: immunohistochemistry \[ihc\] 3+ and or fluorescence in situ hybridization \[fish\] amplified; triple negative: estrogen receptor \[er\] and progesterone receptor \[pr\] \< 1%, her2 negative \[ihc 1+ or 2+ fish non-amplified\]) * age ≥ 18 years and ≤ 80 years. * the primary tumor must be excised via breast conserving surgery. * stage p t1-2 n0 m0 * ecog performance status ≤2. exclusion criteria: * invasive breast cancer not confirmed by pathology. * distant metastasis * prior thoracic radiation. * pregnancy or lactating.

Keywords: breast cancer her2 positive triple negative proton and carbon ion dose escalation
retrospective evaluation of the effect of iron (fe) infusion on complications in anemic patients undergoing thoracotomy

Conditions: Iron Deficiency Anemia; Iron Deficiency Anemia Treatment

Summary: in patients who underwent thoracotomy due to lung malignancy; it is desired to investigate whether there is a difference in terms of postoperative results between those with and without anemia, and those with iron deficiency anemia (ida) who underwent intravenous iron replacement and those who did not, according to the hemoglobin value in their preoperative examinations.


Eligibility criteria:
inclusion criteria: * thoracotomy patients exclusion criteria: * emergency cases
the epidemiology, process and outcomes of spine oncology (eposo)

Conditions: Secondary Malignant Neoplasm of Vertebral Column

Summary: the main purpose of this study is to utilize a comprehensive, prospective clinical database to collect patient, diagnostic and treatment variables along with disease specific and generic health related quality of life (hrqol) data on consecutively treated patients with metastatic spine tumors. the objectives are to determine the validity and reliability of the spine cancer outcomes questionnaire (scoq) for use in the assessment of spine tumor outcomes, to determine if the spine instability neoplastic score (sins) classification is a valid tool for predicting the stability of spine in metastatic spine disease, and to determine the efficacy of surgery versus radiotherapy for the treatment of impending instability secondary to metastatic disease of the spine.


Eligibility criteria:
inclusion criteria: * signed informed consent * age between 18 and 75 years * able to read and write english at an elementary level * diagnosis of metastatic tumor of the spine exclusion criteria: * the primary cancer site is central nervous system or spine * history of substance abuse (recreational drugs, alcohol) within 12 months prior to screening * is a prisoner * a disease or condition that would, in opinion of the investigator, preclude accurate evaluation (e.g. significant psychiatric disease)
stem cell therapy for chronic kidney disease

Conditions: Chronic Kidney Diseases; Diabetes Mellitus, Type 2; Diabetes Mellitus, Type 1; Diabetes Mellitus; Diabetic Nephropathies

Summary: the purpose of this study is to assess the safety and tolerability of allogeneic mesenchymal stem / stromal cell therapy in individuals with chronic kidney disease.


Eligibility criteria:
inclusion criteria: * age 30-80 years. * estimated glomerular filtration rate (egfr) 25-55 ml/min/1.73m\^2 * spot urine albumin:creatinine ≥30 mg/g unless on renin-angiotensin-aldosterone system (raas) inhibition. * ability to give informed consent. exclusion criteria: * hemoglobin a1c greater than or equal to 11%.(in individuals with diabetes mellitus) * anemia (hemoglobin less than 9g/dl) * body weight greater than 150 kg or bmi greater than 50 * uncontrolled hypertension: sustained systolic blood pressure (sbp) greater than 155 mmhg at screening exam (a maximum of 3 screening visits will be allowed for demonstration of blood pressure control) * chronic hypotension: sustained sbp less than 85 mmhg at screening exam. * glomerulonephritis not in partial or complete remission for 6 months (or estimated/measured proteinuria greater than 10 grams/day) * active glomerulonephritis (glomerular disease) include: anca associated glomerulonephritis, post-infectious glomerulonephritis, lupus nephritis, amyloidosis, or other monoclonal gammopathy of renal significance. * nephrotic syndrome defined as proteinuria greater than 3.5g per 24 hours, plus hypoalbuminemia (serum albumin less than or equal to 2.5g/l) and edema * autosomal dominant or recessive polycystic kidney disease * kidney failure requiring renal replacement therapy (hemodialysis, peritoneal dialysis, or kidney transplantation) * active immunosuppression therapy (including prednisone greater than or equal to 10mg daily) * kidney transplantation history * solid organ transplantation history * recent cardiovascular event (myocardial infarction, stroke, congestive heart failure) within 6 months or uncontrolled cardiac arrhythmias * liver cirrhosis * chronic obstructive pulmonary disease, asthma * history of blood clotting disorder (thromboembolism; pulmonary embolism, deep venous thrombosis) * pregnancy * active malignancy * active infection * active hepatitis b or c, or hiv infection * history of allergic reaction to cellular products (ie. blood transfusions, platelets) * active tobacco use * illicit drug use and excessive alcohol use presence of psychosocial issues (e.g., uncontrolled mental illness, unpredictable childcare or eldercare responsibilities, irregular/inflexible work schedule) that may interfere with the ability to complete all study procedures * subjects anticipating prolonged travel or other physical restrictions that would prohibit return for scheduled study visits * inability or unwilling to have magnetic resonance imaging (mri) or computed tomography (ct) studies * inability to give informed consent

Keywords: stem cell mesenchymal stem cell mesenchymal stromal cell diabetes mellitus diabetic nephropathy diabetic kidney disease kidney gfr
endoscopic harvesting in coronary artery bypass grafting.

Conditions: Coronary Bypass Stenosis; Graft Infection

Summary: this is a retrospective data collection looking at patients who received either an endoscopic vessel harvesting procedure versus the conventional open procedure. besides looking at cost variables in the 2 groups, other outcomes of interest include length of hospital stay, rates of infection, medication use, re-admissions and compilations.

since april 2018, the study database has been updated with all patients (currently there are 340 patients per group) and variables - both reflecting effectiveness of the procedure and cost. preoperative variables being captured include comorbidity factors and variables relating to the society of thoracic surgery (sts) score , which is a pre-procedure assessment of surgical risk. the postoperative data collection includes a variety of complications and comorbidities the patient could experience during their hospital stay. these variables will provide us with information regarding procedure effectiveness, patient recovery and further costs associated with the procedure. medications and antibiotics provided during the stay are also being captured. total hospital costs will include any costs associated with ward stay, separated per level of care: intensive care unit (icu), cardiac surgical unit (csu), and regular ward. the two follow up periods are 30 days and 6 months. both look at the same effectiveness variables, any emergency room (er) visits, re-admissions, and their respective reasons. quality of life will be obtained by looking at the number of complications the patient experienced during these periods. the frequency of home care services provided to each patient, if any, are also being tracked. cost calculations will be done by obtaining the time, length and number of visits to the er, re-admissions and clinic visits.

Eligibility criteria:
inclusion criteria: * any patient at the khsc undergoing a cabg procedure requiring a vein graft. exclusion criteria: * undergoing a simultaneous procedure.
the 3q29 deletion and 3q29 duplication: architecture of behavioral phenotypes

Conditions: Microdeletion 3q29 Syndrome; Microduplication 3q29 Syndrome

Summary: the 3q29 deletion syndrome is caused by a deletion of a small part of human chromosome 3, and the duplication syndrome is caused by a duplication of this same small region. the purpose of this study is to understand the medical and behavioral consequences of these syndromes.

people with 3q29 deletion syndrome are missing a small part of a region on human chromosome 3, and people with 3q29 duplication syndrome have an extra part of their chromosome 3. sometimes babies are born with a deletion or duplication of part of human chromosome 3, even though their parents have an intact chromosome 3. this is called de novo (or new) abnormalities.

Eligibility criteria:
inclusion criteria: * diagnosis of 3q29 deletion or 3q29 duplication * consent from parents or guardians or an adult with 3q29 deletion or 3q29 duplication that does not require a legal guardian or an adult who is the healthy sibling of an individual with 3q29 deletion or 3q29 duplication or a healthy age-matched control exclusion criteria: * clinically significant medical disease that would prohibit participation in the study procedures